The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients. While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.
【저자키워드】 SARS-CoV-2, Antiviral agents, 【초록키워드】 Treatment, Vaccine, Antiviral, SARS-COV-2 infection, COVID-19 pandemic, Human, Infection, drug, Region, animals, utility, SARS-CoV-2 replication, COVID-19 patients, Evidence, Support, These data, inhibitory effect, treatment of COVID-19 patients, nucleoside, while, Administered, effective, benefit, inhibit, approved, 【제목키워드】 inhibit,